Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - lisinopril dihydrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - lisinopril dihydrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - lisinopril dihydrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

fair-med healthcare australia pty ltd - lisinopril dihydrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

fair-med healthcare australia pty ltd - lisinopril dihydrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

fair-med healthcare australia pty ltd - lisinopril dihydrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - lisinopril dihydrate, quantity: 22.22 mg (equivalent: lisinopril, qty 20 mg) - tablet, uncoated - excipient ingredients: mannitol; calcium hydrogen phosphate dihydrate; pregelatinised maize starch; croscarmellose sodium; magnesium stearate; iron oxide red; iron oxide black; iron oxide yellow - hypertension: lisinopril hexal is indicated in the treatment of mild to moderate essential hypertension. it may be used alone or concomitantly with other classes of antihypertensive agents. sufficient data have nor been provided to support the use of lisinopril in severe hypertension or renovascular hypertension. congestive heart failure: lisinopril hexal is also indicated in the treatment of heart failure. in such patients, it is recommended the lisinopril hexal be administered together with a diuretic. acute myocardial infarction: lisinopril hexal is indicated for the treatment of acute myocardial infarction in haemodynamically stable patients, defined as patients who are not in cardiogenic shock and who have a systolic blood pressure greater than 100 mmhg. lisinopril hexal may be initiated within 24 hours of an acute myocardial infarction.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - lisinopril dihydrate, quantity: 10.89 mg (equivalent: lisinopril, qty 10 mg) - tablet, uncoated - excipient ingredients: calcium hydrogen phosphate dihydrate; mannitol; maize starch; pregelatinised maize starch; magnesium stearate; colloidal anhydrous silica - hypertension: treatment of hypertension. lisinopril may be used alone or concomitantly with other classes of antihypertensive agents. sufficient data have not been provided to support the use of lisinopril in severe hypertension or renovascular hypertension. congestive heart failure: treatment of heart failure. in such patients, it is recommended that lisinopril be administered together with a diuretic. acute myocardial infarction: treatment of acute myocardial infarction in haemodynamically stable patients, defined as patients who are not in cardiogenic shock and who have a systolic blood pressure greater than 100 mmhg. lisinopril may be initiated within 24 hours of an acute myocardial infarction.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - lisinopril dihydrate, quantity: 5.445 mg (equivalent: lisinopril, qty 5 mg) - tablet, uncoated - excipient ingredients: calcium hydrogen phosphate dihydrate; mannitol; maize starch; pregelatinised maize starch; magnesium stearate; colloidal anhydrous silica - hypertension: treatment of hypertension. lisinopril may be used alone or concomitantly with other classes of antihypertensive agents. sufficient data have not been provided to support the use of lisinopril in severe hypertension or renovascular hypertension. congestive heart failure: treatment of heart failure. in such patients, it is recommended that lisinopril be administered together with a diuretic. acute myocardial infarction: treatment of acute myocardial infarction in haemodynamically stable patients, defined as patients who are not in cardiogenic shock and who have a systolic blood pressure greater than 100 mmhg. lisinopril may be initiated within 24 hours of an acute myocardial infarction.

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - lisinopril (unii: e7199s1ywr) (lisinopril anhydrous - unii:7q3p4bs2fd), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - lisinopril 20 mg - lisinopril and hydrochlorothiazide t ablets are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including lisinopril and hydrochlorothiazide. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than 1 drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerous antihypertensive drugs, from a var